Palmitoyl Tripeptide-1
Also known as: Pal-GHK, Biopeptide CL, Part of Matrixyl 3000
Palmitoyl Tripeptide-1 (also called Pal-GHK or Biopeptide CL) is a cosmetic copper-free GHK analog in the Copper Peptide class. Palmitoyl tripeptide-1 delivers the GHK sequence with a sixteen-carbon palmitic acid chain attached to the N-terminus. The lipid tail greatly increases lipophilicity, which is intended to improve partitioning into the stratum corneum, the main barrier to topical peptide delivery.
For research use only.
Key Facts
- CAS
- 147732-56-7
- Molecular Weight (MW)
- ≈578.8 g/mol
- Half-life
- Topical; systemic PK not established
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Dermal fibroblasts
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 2
- Listed offers
- 2
- Price per mg
- $0.250/mg
Research summary
The GHK tripeptide supplied with a palmitic acid chain attached to improve penetration through the outer skin barrier, and without the bound copper of GHK-Cu. It is used topically as a matrikine, a peptide fragment that signals matrix turnover to dermal fibroblasts, and is most often formulated alongside palmitoyl tetrapeptide-7. Regulated as a cosmetic ingredient rather than a drug, and not FDA-approved for any therapeutic use.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studies2 reviewed sources
- Lab & animal studies1 reviewed source
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Palmitoyl Tripeptide-1 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Palmitoyl Tripeptide-1 dosage: no established human dose
Palmitoyl tripeptide-1 (pal-GHK) has no established human dosage. It is a cosmetic ingredient, often paired with palmitoyl tetrapeptide-7 as Matrixyl 3000. No controlled human study naming it could be confirmed; the human data found are an uncontrolled eye-cream study and a three-person skin-permeation study.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Palmitoyl tripeptide-1 is the tripeptide GHK linked to palmitic acid, without copper. Its human data are small studies of blends that cannot isolate its effect. There is no human study of it given by injection, so no injectable amount, route or interval is established.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Topical (cosmetic use); not established for injection |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Human research reported
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Clinical study — multi-ingredient eye cream (Yang et al., 2024)Clinical trial · Clinical study of a multi-ingredient product; a control group is not stated in the abstract | Adults using the eye cream (number not stated in the indexed abstract) | Not stated in the indexed abstract; the cream combined a yeast/rice ferment filtrate, N-acetylneuraminic acid, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 | Topical (periorbital area) | — | 12 weeks | Skin hydration +28.12%, elasticity +18.81% and ultrasound collagen measure +54.99% at 12 weeks; reported as well tolerated | Yang F et al. Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream. Skin Res Technol. 2024. |
| Skin permeation in volunteers — Matrixyl 3000 serum (Trzaska et al., 2026)Clinical trial · Small skin-permeation study in people (no efficacy outcome) | 3 healthy women | Serum strength not stated in the indexed abstract | Topical, then tape stripping of the stratum corneum | — | Single exposures of 0.5, 2 and 5 hours | Both palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 were found through every layer of the stratum corneum, between the cells rather than inside them, at falling levels with depth | Trzaska AH et al. Permeation behaviour of cosmetic actives into the human stratum corneum. Int J Pharm. 2026. |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Laboratory study — collagen screening of cosmetic peptides (Zang et al., 2026)Preclinical · In vitro and ex vivo study | Human dermal fibroblasts and ex vivo skin | Not stated in the indexed abstract | Applied to cells and skin samples in the laboratory | — | — | Palmitoyl tripeptide-1 was one of four peptides that raised type III collagen after UV exposure without detectable cytotoxicity; the combination had a larger effect than single peptides | Zang S et al. Mechanistic understanding and peptide ingredient screening for type III collagen via biological knowledge graph and molecular docking. Int J Cosmet Sci. 2026. |
Where sources disagree
- A percentage or ppm in a cream is a formulation strength, not a dose, and cannot be converted into an amount for injection.
- GHK-Cu studies are not evidence for palmitoyl tripeptide-1. The copper complex and the palmitoylated peptide are different molecules.
- A placebo-controlled study of palmitoyl tetrapeptide-7 paired it with "palmitoyl oligopeptide"; its abstract does not say whether that is palmitoyl tripeptide-1, so it is not counted here.
Sequence & molecular data
| Molecular formula | C30H54N6O5 |
|---|---|
| Molecular weight | ≈578.8 g/mol |
| CAS number | 147732-56-7 |
| Half-life | Topical; systemic PK not established |
| Appearance | White powder |
| Formulation | Topical Cream |
| PubChem CID | 10231864 |
| FDA UNII | RV743D216M |
| DrugBank | DB11297 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Palmitoyl tripeptide-1 delivers the GHK sequence with a sixteen-carbon palmitic acid chain attached to the N-terminus. The lipid tail greatly increases lipophilicity, which is intended to improve partitioning into the stratum corneum, the main barrier to topical peptide delivery. Unlike GHK-Cu it is supplied without bound copper. It is described as a matrikine — a peptide fragment that signals extracellular matrix turnover to dermal fibroblasts — and supplier studies report increased collagen and glycosaminoglycan synthesis in fibroblast assays. It is most often formulated alongside palmitoyl tetrapeptide-7, and most published data concerns those finished combinations rather than the isolated ingredient.
Origin
Synthetic palmitoyl-GHK.
Targets
Studies
- EGCG-Biotin-Pal-GHK composition modulates TGF-β and BMP pathways in scalp microenvironment for treating stress-induced alopecia
- Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective
- Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism
- Palmitoyl copper peptide and acetyl tyrosine complex enhances melanin production in both A375 and B16 cell lines
- Development of a LC-MS/MS method to monitor palmitoyl peptides content in anti-wrinkle cosmetics
Research statistics
5 PubMed publications · 40.0% human clinical research · 0 registered trials
Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Palmitoyl Tripeptide-1 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | OTC / Supplement |
| WADA (sport) | Permitted |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Palmitoyl Tripeptide-1 side effects
Palmitoyl Tripeptide-1 has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Irritation
Stacking
Common stacking partners
Combinations that include Palmitoyl Tripeptide-1, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Palmitoyl Tripeptide-1: frequently asked questions
What is Palmitoyl Tripeptide-1?
The GHK tripeptide supplied with a palmitic acid chain attached to improve penetration through the outer skin barrier, and without the bound copper of GHK-Cu. It is used topically as a matrikine, a peptide fragment that signals matrix turnover to dermal fibroblasts, and is most often formulated alongside palmitoyl tetrapeptide-7. Regulated as a cosmetic ingredient rather than a drug, and not FDA-approved for any therapeutic use.
How does Palmitoyl Tripeptide-1 work?
Palmitoyl tripeptide-1 delivers the GHK sequence with a sixteen-carbon palmitic acid chain attached to the N-terminus. The lipid tail greatly increases lipophilicity, which is intended to improve partitioning into the stratum corneum, the main barrier to topical peptide delivery.
Is Palmitoyl Tripeptide-1 FDA approved?
No. Palmitoyl Tripeptide-1 is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Palmitoyl Tripeptide-1?
Reported half-life for Palmitoyl Tripeptide-1 is Topical; systemic PK not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Palmitoyl Tripeptide-1 banned in sport?
Palmitoyl Tripeptide-1 is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to Palmitoyl Tripeptide-1?
Compounds most often compared with Palmitoyl Tripeptide-1 include GHK-Cu (Copper Peptide), AHK-Cu, Acetyl Hexapeptide-8 and Acetyl Octapeptide-3. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- EGCG-Biotin-Pal-GHK composition modulates TGF-β and BMP pathways in scalp microenvironment for treating stress-induced alopecia — Eur J Pharmacol, 2026External reference
- Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective — Bioimpacts, 2025External reference
- Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism — J Cosmet Dermatol, 2026External reference
- Palmitoyl copper peptide and acetyl tyrosine complex enhances melanin production in both A375 and B16 cell lines — Biochem Biophys Res Commun, 2025External reference
- Development of a LC-MS/MS method to monitor palmitoyl peptides content in anti-wrinkle cosmetics — Anal Chim Acta, 2009External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Palmitoyl Tripeptide-1 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Palmitoyl Tripeptide-1 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →